Butixocort propionate
Alternative Names: Butixacord; JO 1222Latest Information Update: 12 Jul 2000
Price :
$50 *
At a glance
- Originator Jouveinal
- Developer 3M Pharmaceuticals
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Arachidonic acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 12 Jul 2000 No-Development-Reported for Allergic rhinitis in European Union (Intranasal)
- 12 Jul 2000 No-Development-Reported for Asthma in European Union (Inhalation)
- 21 Jun 2000 Warner-Lambert has merged with Pfizer